期刊文献+

人胃癌耐药细胞株SGC-7901/HCPT的耐药机制初探 被引量:1

The Drug Resistance Mechanism of the Camptothecin(HCPT)-resistant Stomach Cancer Cell Line SGC-7901/HCPT
暂未订购
导出
摘要 目的:探讨人胃癌耐羟基喜树碱细胞株即SGC-7901/HCPT的耐药机制。方法:通过光镜和电镜观测SGC-7901/HCPT与人胃癌细胞株即SGC-7901形态和超微结构差异和免疫细胞化学的方法检测SGC-7901/HCPT与SGC-7901之间的TOPO-Ⅰ、TOPO-Ⅱ、P-gp、GST-π、BCL-2表达异同来探讨SGC-7901/HCPT的可能耐药机制。结果:(1)光镜下SGC-7901/HCPT细胞大小不一致,形态不规则,胞浆较丰富,核小而不规则,可见巨核现象;而SGC-7901细胞呈圆梭形,大小一致,核圆形;电镜下SGC-7901/HCPT表面指状突起明显,胞浆内有较多的核糖体及粗面内质网,线粒体较多。(2)SGC-7901/HCPT的TOPO-Ⅰ表达较SGC-7901明显增加,差异具有显著性;而TOPO-Ⅱ、P-gp、GST-π、BCL-2的表达差异无显著性。结论:SGC-7901/HCPT趋向细胞成熟分化,这可能是其产生耐药的形态学表现。TOPO-Ⅰ的表达下降则可能是SGC-7901/HCPT耐HCPT形成的分子基础。 Objective: To investigate drug- resistance mechanism of the camptothecin (HCPT)-resistant stomach cancer cell line SGC-7901/HCPT. Methods: The ceil image and its ultra micro-structure of parental and resistant ceils were observed with the optical microscope and electron microscope. Expression of TOPO- Ⅰ , TOPO- Ⅱ α, P-gp, GST-π and BCL-2 of parental and resistant cells were assessed with S-P immunocytochemical Method. Results: The size of the SGC-7901/HCPT cells were different, with irregular shape and more abundant cytoplasm, small and irregular nucleus, many of them with a lobulate nucleus under the optical microscope. The SGC-7901 has similar size and regular shape, with fewer cytoplasm, regular and large nucleolus. Ribosome, rough endoplasmic reticulums and mitochondria in SGC-7901/HCPT increased under electron microscope. The expression level of TOPO- Ⅰ in SGC-7901/HCPT showed a significant reduction than that of the parent ceil line( P 〈 0. 05 ). The staining of TOPO-Ⅱ α, P-gp, GST-π and BCL-2 are no significant different between them. Conclusion: Our results suggest that ceil differentiation toward the maturity and down regulated expression of TOPO-Ⅰ are correlated to the drug resistance of the camptothecin-resistant stomach cancer ceil line.
出处 《四川肿瘤防治》 2007年第1期10-12,共3页 Sichuan Journal of Cancer Control
基金 四川省科技厅基金资助课题(02SC02-077)
关键词 人胃癌细胞株 羟基喜树碱 耐药 Human Stomach Cancer Cell Line Camptothecin Drag Resistance
  • 相关文献

参考文献6

二级参考文献27

  • 1Fukuoka K, Adachi J, Nishio K, et al. p16^INK4 expression is associated with the increased sensitivity of human non-small cell lung cells to DNA topoisomerase Ⅰ inhibitors. Jpn J Cancer Res, 1997, 88 (10):1009-1016.
  • 2Desai SD, Li TK, Rodriguez-Bauman A, et al. Ubiquitin/26S proteasome-mediated degradation of topoisomerase Ⅰ as a resistance mechanism to camptothecin in tumor cells. Cancer Res, 2001, 61 (15):5926-5932.
  • 3Urasaki Y, Laco GS, Pourquier P, et al. Characterization of a novel topoisomerase Ⅰ mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res, 2001, 61(5): 1964-1969.
  • 4Wang LF, Ting CY, Lo CK, et al. Identification of mutations at DNA topoisomerase Ⅰ responsible for camptothecin resistance. Cancer Res,1997, 57(8): 1516-1522.
  • 5Jacob S, Aguado M, Fallik D, et al. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res,2001, 61(17): 6555-6562.
  • 6Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A, 1998, 95(26): 15665-15670.
  • 7Ma J, Maliepaard M, Nooter K, et al. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer, 1998, 77(10): 1645-1652.
  • 8Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res, 1999, 59(18): 4559-4563.
  • 9Yang CH, Schneider E, Kuo ML, et al. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. BiochemPharmacol, 2000, 60(6): 831-837.
  • 10Scheffer GL, Maliepaard M, Pijnenborg AC, et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone and topotecan-resistant cell lines. Cancer Res, 2000, 60(10): 2589-2593.

共引文献28

同被引文献6

  • 1翟宝进,伍烽,邵泽勇,胡凯,赵纯亮,王智彪.人肝癌移植瘤多药耐药模型的建立及耐药机制的探讨[J].癌症,2004,23(8):905-909. 被引量:5
  • 2Thomas H,Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein [ J ]. Cancer Control,2003,10 ( 2 ) : 159 - 165.
  • 3Harrington D J, Lessey BA, Rai V, et al. Tenascin is differentially expressed in endometrium and endometriosis [ J ]. J Pathol, 1999, 187(2) :242 -248.
  • 4Fukuoka K, Adachi J, NishioKt, et al. pl6INK4 expressionis asso- ciated with the increased sensitivity of human non - small cell lung cells to DNA topoisomerase 1 inhibitors [ J ]. JPn J Cancer Res, 1997,88(10) :1009 - 1016.
  • 5Beidler DR, Chang JY,Zhou BS, et a/. Camptotheein resistance in- volving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines [ J ]. Cancer Res,1996,56(2) :345 -353.
  • 6ho K, Nagura H, Yajima A, et al. Immunohistochemical study of Ki-67 and DNA topoisomerase II in human endometrium[ J]. Mod Pathol, 1997,10 ( 3 ) :289 - 294.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部